Jerome Becquart JEROME BECQUART is founder and CEO of Brainvectis. He has 20 years’ industrial experience in pharmaceutical research and development at Aventis (now Sanofi) where he held different management positions in the biotechnology and lead discovery departments and as a member of the Paris research Center.

Since 2004, his entrepreneur experience includes the creation of biotech startups specialized in drug development (in metabolic and neurological diseases) and in services to the pharmaceutical industry. As a consultant, Jérôme advised many different companies in the biotech field. Jérôme graduated from Ecole Centrale Paris and obtained his PhD in biochemistry from Paris university.

Jerome Becquart, PhD


NATHALIE CARTIER-LACAVE is founder and CSO of BrainVectis.

Research Director at INSERM, where she leads the group “Biotherapies of neurodegenerative diseases”, Nathalie is president of the European Society of Gene and Cell Therapy (ESGCT).

Her research led to the first gene therapy clinical trial in humans, using HIV as a gene transfer vector (Science 2009). Thanks to this trial, four children suffering from adrenoleukodystrophy were cured.

She has been interested in the link between cholesterol and neurodegenerative diseases for 10 years.

Nathalie Cartier-Lacave, MD


Michel ZerahMICHEL ZERAH oversees the design of the neurosurgical protocols.

Physician, chief of neurosurgery unit at Hopital Necker in Paris, Michel Zerah is investigator in CNS gene therapy clinical trials (Sanfilippo disease, Metachromatic leucodystrophy).

Michel Zerah, MD


Sandro AlvesSANDRO ALVES, PhD, 12 year-expertise in research for neurodegenerative disorders and gene therapy, is director of preclinical studies at Brainvectis.

Sandro leads the Brainvectis Preclinical Research Office and directs the preclinical activity on Alzheimer’s disease and Huntington’s disease. He is also involved in the scientific consideration of future therapeutic strategies to be developed in other neurodegenerative disorders.

Prior to joining Brainvectis, Sandro conducted his research at the Brain and Spine Institute (Paris), evaluating therapeutic strategies in animal models of Spinocerebellar ataxia and then at MIRCen/CEA, developing therapeutic research in animal models of Alzheimer’s and Huntington’s disease.

Sandro obtained his PhD in Health Sciences and Technology (Neuroscience) from the Center for Neuroscience and the Faculty of Pharmacy of the University of Coimbra (Portugal), in 2008, where he developed gene therapy correction in animal models of Machado-Joseph disease.

Sandro Alves, PhD


Aurelie BerniardAURELIE BERNIARD has worked for 7 years in preclinical research in the field of oncology and neurosciences.

Before joining BrainVectis, she spent 2 years within Neurodegenenerative Diseases Laboratory of CEA working on gene therapy for Huntington disease.

Aurélie graduated from Bordeaux University where she obtained her master degree in Neurosciences and Neuropharmacology.

Aurelie Berniard


Scientific advisers

Jocelyne Caboche (INSERM/UMR-S 1130, CNRS/UMR 8246)
Sandrine Betuing (INSERM/UMR-S 1130, CNRS/UMR 8246)
Alexandra Durr (ICM / Hôpital Pitié-Salpêtrière)